Skip to main content
. Author manuscript; available in PMC: 2015 Feb 15.
Published in final edited form as: Cancer Res. 2013 Dec 16;74(4):1045–1055. doi: 10.1158/0008-5472.CAN-13-2908

Figure 4.

Figure 4

Immunization with MHC class I and class II peptides augments cytotoxic potential and lytic function of TA-specific CTLs. (A) Flow cytometry dot plots of total CD8+ T cells from four selected melanoma patients (MP) in arm 1 (left panel) and arm 2 (right panel), showing ex vivo percentage of NY-ESO-1 tet+ CD8+ T cells among total CD8+ T cells that express granzyme A, granzyme B, or perforin after vaccination. (B) After- versus before- vaccination differences in the percentage of granzyme A, granzyme B and perforin-expressing cells among total vaccine-induced NY-ESO-1-specific CD8+ T cells, in patients from arm 1 (n = 5) and arm 2 (n = 7). For patients with no NY-ESO-1-specific CD8+ T cell response before vaccination, pre-vaccine percentages of cytotoxic marker-expressing cells were considered to be 0. (C) Flow cytometry dot plots of total CD8+ T cells from four melanoma patients in arm 1 (left panel) and arm 2 (right panel), showing ex vivo percentages of CD107a - and CD107a+ NY-ESO-1 tet+ CD8+ T cells among total CD8+ T cells after vaccination. (D) After- versus before- vaccination differences in the percentages of CD107a+ cells within total vaccine-induced NY-ESO-1-specific CD8+ T cells, in patients from arm 1 (n = 5) and arm 2 (n = 7). Horizontal bars, means. Open circles, arm-1 patients, grey circles, arm-2 patients. *, P < 0.05 was considered significant. Data shown are from of two independent experiments.